How McKesson’s New Defensive Index Roles and TempraMed Expansion Will Impact McKesson (MCK) Investors

Simply Wall St.07:17

In late June 2026, McKesson Corporation was added to the Russell 1000 Defensive, Russell 1000 Value-Defensive, and Russell 1000 Growth-Defensive indexes, while partner TempraMed expanded its ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2648059311?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/288195-main-header/1756206015044","is_english":true,"pubTime":"2026-07-01 07:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2648059311","market":"sg","top_or_hot":-1,"title":"How McKesson’s New Defensive Index Roles and TempraMed Expansion Will Impact McKesson (MCK) Investors","media":"Simply Wall St.","content":"<div>\n<p>In late June 2026, McKesson Corporation was added to the Russell 1000 Defensive, Russell 1000 Value-Defensive, and Russell 1000 Growth-Defensive indexes, while partner TempraMed expanded its ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-mck/mckesson/news/how-mckessons-new-defensive-index-roles-and-tempramed-expans\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How McKesson’s New Defensive Index Roles and TempraMed Expansion Will Impact McKesson (MCK) Investors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow McKesson’s New Defensive Index Roles and TempraMed Expansion Will Impact McKesson (MCK) Investors\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-01 07:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-mck/mckesson/news/how-mckessons-new-defensive-index-roles-and-tempramed-expans><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In late June 2026, McKesson Corporation was added to the Russell 1000 Defensive, Russell 1000 Value-Defensive, and Russell 1000 Growth-Defensive indexes, while partner TempraMed expanded its ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-mck/mckesson/news/how-mckessons-new-defensive-index-roles-and-tempramed-expans\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1585245621.USD","symbol_name":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-mck/mckesson/news/how-mckessons-new-defensive-index-roles-and-tempramed-expans","article_id":"2648059311","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/288195-main-header/1756206015044"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-mck/mckesson/news/how-mckessons-new-defensive-index-roles-and-tempramed-expans","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2648059311","pubTimestamp":1782861457,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In late June 2026, McKesson Corporation was added to the Russell 1000 Defensive, Russell 1000 Value-Defensive, and Russell 1000 Growth-Defensive indexes, while partner TempraMed expanded its distribution agreement with McKesson Medical-Surgical across North America to deepen access to temperature-controlled medication solutions.\nThese developments highlight how McKesson is increasingly positioned as a core defensive healthcare distributor while extending its reach into specialized,...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1037948897.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (HKD) INC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU0965508806.USD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (USD) INC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1814569148.SGD":"WELLINGTON GLOBAL QUALITY GROWTH \"D\" (SGDHDG) ACC","LU1934455277.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"AD\" (USD) INC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU1037948541.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (HKD) ACC","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU1934455194.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (USD) ACC","LU1506573853.SGD":"MANULIFE GF GLOBAL EQUITY \"AA\" (SGD) INC","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","LU0942090050.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD)  INC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1934455863.HKD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (HKD) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","BK4588":"碎股","LU0689626769.HKD":"AB SICAV I - SUSTAINABLE US THEMATIC PORTFOLIO \"A\" (HKD) ACC","LU0965509101.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (SGDHDG) ACC","LU0742534661.SGD":"Fidelity America A-SGD (hedged)","LU0882574055.USD":"富达全球健康医疗A ACC","LU0868494708.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) INC","LU0861579265.USD":"联博低波幅策略股票基金A","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","BK4211":"区域性银行","LU0122379950.USD":"贝莱德世界健康科学A2","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","ISBC":"投资者银行","BK4585":"ETF&股票定投概念","LU1983260115.SGD":"Janus Henderson Horizon Global Sustainable Equity A2 SGD-H","BK4175":"保健护理产品经销商","LU0251131958.USD":"FIDELITY AMERICA \"A\" (USD) ACC","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","LU0048573561.USD":"FIDELITY AMERICA \"A\" (USD) INC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU0251142724.SGD":"Fidelity America A-SGD","LU0314106906.USD":"MANULIFE GF GLOBAL EQUITY \"AA\" (USD) INC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","MCK":"麦克森药物批发","LU0124676726.USD":"AB SICAV I - SUSTAINABLE US THEMATIC PORTFOLIO \"A\" (USD) ACC"},"translate_title":"McKesson的新防御性指数角色和TempraMed扩张将如何影响McKesson(MCK)投资者","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MCK":1.5,"ISBC":1.5},"content_text":"In late June 2026, McKesson Corporation was added to the Russell 1000 Defensive, Russell 1000 Value-Defensive, and Russell 1000 Growth-Defensive indexes, while partner TempraMed expanded its distribution agreement with McKesson Medical-Surgical across North America to deepen access to temperature-controlled medication solutions. These developments highlight how McKesson is increasingly positioned as a core defensive healthcare distributor while extending its reach into specialized, higher-value medication handling through broader TempraMed integration. Next, we’ll examine how McKesson’s new defensive index inclusions and expanded TempraMed partnership may influence its existing investment narrative. Uncover the next big thing with 22 elite penny stocks that balance risk and reward.AdvertisementMcKesson Investment Narrative RecapTo own McKesson, you generally need to believe in its role as a scale healthcare distributor with growing exposure to complex, higher-value pharmaceuticals and services. The new Russell defensive index inclusions and the broader TempraMed rollout do not materially change the near term focus on execution in specialty and oncology services or the key risk around policy-driven pressure on drug pricing and margins. The TempraMed expansion across North America is most relevant here, because it ties directly into McKesson’s push into more complex cold chain and specialty medication handling, where operational capabilities can support its existing catalysts in specialty, oncology, and value-added services. Yet investors should also weigh how rising regulatory scrutiny on drug pricing could affect McKesson’s margins and capital returns... Read the full narrative on McKesson (it's free!)McKesson's narrative projects $499.3 billion revenue and $6.1 billion earnings by 2029. This requires 7.4% yearly revenue growth and about a $1.3 billion earnings increase from $4.8 billion today.Uncover how McKesson's forecasts yield a $941.40 fair value, a 25% upside to its current price.Exploring Other PerspectivesMCK 1-Year Stock Price Chart Six fair value estimates from the Simply Wall St Community range from about US$2 to US$941 per share, underlining how far apart views on McKesson can be. Against that backdrop, understanding the risk that tighter drug pricing regulation could pressure margins and reshape expectations for its defensive profile becomes especially important as you compare these different viewpoints.Explore 6 other fair value estimates on McKesson - why the stock might be worth less than half the current price!Decide For YourselfDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your McKesson research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision.Our free McKesson research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate McKesson's overall financial health at a glance.Want Some Alternatives?Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2648059311","isCrawlerRequest":true}